Literature DB >> 22933399

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Conrad P Quinn1, Carol L Sabourin, Nancy A Niemuth, Han Li, Vera A Semenova, Thomas L Rudge, Heather J Mayfield, Jarad Schiffer, Robert S Mittler, Chris C Ibegbu, Jens Wrammert, Rafi Ahmed, April M Brys, Robert E Hunt, Denyse Levesque, James E Estep, Roy E Barnewall, David M Robinson, Brian D Plikaytis, Nina Marano.   

Abstract

A 3-dose (0, 1, and 6 months) intramuscular (3-IM) priming series of a human dose (HuAVA) and dilutions of up to 1:10 of anthrax vaccine adsorbed (AVA) provided statistically significant levels of protection (60 to 100%) against inhalation anthrax for up to 4 years in rhesus macaques. Serum anti-protective antigen (anti-PA) IgG and lethal toxin neutralization activity (TNA) were detectable following a single injection of HuAVA or 1:5 AVA or following two injections of diluted vaccine (1:10, 1:20, or 1:40 AVA). Anti-PA and TNA were highly correlated (overall r(2) = 0.89 for log(10)-transformed data). Peak responses were seen at 6.5 months. In general, with the exception of animals receiving 1:40 AVA, serum anti-PA and TNA responses remained significantly above control levels at 28.5 months (the last time point measured for 1:20 AVA), and through 50.5 months for the HuAVA and 1:5 and 1:10 AVA groups (P < 0.05). PA-specific gamma interferon (IFN-γ) and interleukin-4 (IL-4) CD4(+) cell frequencies and T cell stimulation indices were sustained through 50.5 months (the last time point measured). PA-specific memory B cell frequencies were highly variable but, in general, were detectable in peripheral blood mononuclear cells (PBMC) by 2 months, were significantly above control levels by 7 months, and remained detectable in the HuAVA and 1:5 and 1:20 AVA groups through 42 months (the last time point measured). HuAVA and diluted AVA elicited a combined Th1/Th2 response and robust immunological priming, with sustained production of high-avidity PA-specific functional antibody, long-term immune cell competence, and immunological memory (30 months for 1:20 AVA and 52 months for 1:10 AVA). Vaccinated animals surviving inhalation anthrax developed high-magnitude anamnestic anti-PA IgG and TNA responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933399      PMCID: PMC3491539          DOI: 10.1128/CVI.00324-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  57 in total

1.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

Authors:  S F Little; B E Ivins; W M Webster; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2005-12-27       Impact factor: 3.641

4.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

5.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Authors:  B W McBride; A Mogg; J L Telfer; M S Lever; J Miller; P C Turnbull; L Baillie
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

7.  Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

Authors:  V A Semenova; E Steward-Clark; K L Stamey; T H Taylor; D S Schmidt; S K Martin; N Marano; C P Quinn
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

8.  Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.

Authors:  Zhaochun Chen; Mahtab Moayeri; Yi-Hua Zhou; Stephen Leppla; Suzanne Emerson; Andrew Sebrell; Fujuan Yu; Juraj Svitel; Peter Schuck; Marisa St Claire; Robert Purcell
Journal:  J Infect Dis       Date:  2006-02-02       Impact factor: 5.226

9.  Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Michael J Gubbins; Jody D Berry; Cindi R Corbett; Jeremy Mogridge; Xin Y Yuan; Lisa Schmidt; Brigitte Nicolas; Amin Kabani; Raymond S Tsang
Journal:  FEMS Immunol Med Microbiol       Date:  2006-08

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  27 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Authors:  Boris Ionin; Robert J Hopkins; Brett Pleune; Gloria S Sivko; Frances M Reid; Kristin H Clement; Thomas L Rudge; Gregory V Stark; Alison Innes; Suha Sari; Tina Guina; Cris Howard; Jeffrey Smith; M Lisa Swoboda; Ekaterina Vert-Wong; Virginia Johnson; Gary S Nabors; Mario H Skiadopoulos
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

3.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

4.  Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Authors:  Eric K Dumas; Lori Garman; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Shyamal Choudhari; William D Picking; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2017-05-11       Impact factor: 3.641

5.  Humoral responses to independent vaccinations are correlated in healthy boosted adults.

Authors:  Lori Garman; Amanda J Vineyard; Sherry R Crowe; John B Harley; Christina E Spooner; Limone C Collins; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Vaccine       Date:  2014-08-17       Impact factor: 3.641

6.  Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.

Authors:  Ligong Chen; Jarad M Schiffer; Shannon Dalton; Carol L Sabourin; Nancy A Niemuth; Brian D Plikaytis; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

7.  Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.

Authors:  G S Sivko; G V Stark; K P Tordoff; K L Taylor; E Glaze; M VanRaden; J M Schiffer; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

8.  Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Authors:  Conrad P Quinn; Carol L Sabourin; Jarad M Schiffer; Nancy A Niemuth; Vera A Semenova; Han Li; Thomas L Rudge; April M Brys; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; Scott D Parker; Janiine Babcock; Wendy Keitel; Gregory A Poland; Harry L Keyserling; Hana El Sahly; Robert M Jacobson; Nina Marano; Brian D Plikaytis; Jennifer G Wright
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

9.  Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.

Authors:  G V Stark; G S Sivko; M VanRaden; J Schiffer; K L Taylor; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-08-22       Impact factor: 3.641

10.  Progress towards the Development of a NEAT Vaccine for Anthrax II: Immunogen Specificity and Alum Effectiveness in an Inhalational Model.

Authors:  Joseph Jelinski; Austen Terwilliger; Sabrina Green; Anthony Maresso
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.